[HTML][HTML] Real-world outcomes and predictive biomarkers for 177Lutetium prostate-specific membrane antigen ligand treatment in metastatic castration-resistant …
M Kafka, A Horninger, G di Santo, I Virgolini… - European Urology …, 2024 - Elsevier
Abstract Background The European Association of Urology guidelines include the lutetium-
177 (177 Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy …
177 (177 Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy …
[HTML][HTML] Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant …
M Kafka, A Horninger… - European …, 2024 - euoncology.europeanurology.com
Abstract Background The European Association of Urology guidelines include the lutetium-
177 (177 Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy …
177 (177 Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy …
Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate …
M Kafka, A Horninger, G di Santo, I Virgolini… - European Urology …, 2023 - europepmc.org
Background The European Association of Urology guidelines include the lutetium-177 (177
Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option for …
Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option for …
Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate …
M Kafka, A Horninger, G di Santo… - EUROPEAN …, 2023 - research.unipd.it
Background: The European Association of Urology guidelines include the lutetium-177
(177Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option …
(177Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option …
Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate …
M Kafka, A Horninger, G di Santo… - European urology …, 2024 - pubmed.ncbi.nlm.nih.gov
Background The European Association of Urology guidelines include the lutetium-177 (177
Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option for …
Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy option for …